HBM Holdings Limited (HKG:2142)

Market Cap	10.08B +247.5%
Revenue (ttm)	908.35M +60.3%
Net Income	573.61M +243.1%
EPS	0.72 +221.3%
Shares Out	835.74M
PE Ratio	16.68
Forward PE	14.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,307,837
Average Volume	2,560,472
Open	11.68
Previous Close	11.68
Day's Range	11.60 - 12.44
52-Week Range	5.32 - 17.98
Beta	1.71
RSI	50.97
Earnings Date	Nov 27, 2025

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 210
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2142

Financial Performance

In 2024, HBM Holdings's revenue was $38.10 million, a decrease of -57.43% compared to the previous year's $89.50 million. Earnings were $2.78 million, a decrease of -87.81%.

Financial numbers in USD